LGS Gut Therapy - Complete and Gentle Acute Care
Testo originale in francese.
LGS Gut Therapy - Complete and Gentle Acute Care, NPN 80077529: prodotto di salute naturale autorizzato in Canada. Ingredienti medicinali: Bifidobacterium animalis subsp. Lactis, Protéase fongique, 4-(1,3;1,4)-bêta-D-glucane 4-glucanohydrolase, Triacylglycérol lipase.
Se questo prodotto fosse venduto in Francia
- Condizioni legali
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
- Condizioni legali
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte | Massimo giornaliero, adulto |
|---|---|---|
| Bifidobacterium animalis subsp. Lactis Fonte : Cellule entière | 9.280.000.000 ufc | Non calcolata |
| Bifidobacterium animalis subsp. Lactis Fonte : BL-04 | 9.280.000.000 ufc | Non calcolata |
| Protéase fongique Fonte : Aspergillus flavus var. oryzae - En entier Potenza : 11.000 FCC HUT | 10,45 milligramme | Non calcolata |
| 4-(1,3;1,4)-bêta-D-glucane 4-glucanohydrolase Fonte : Trichoderma longibrachiatum - En entier Potenza : 1.800 FCC CU | 6,2 milligramme | Non calcolata |
| Triacylglycérol lipase Fonte : Rhizopus oryzae - En entier Potenza : 40 FCC LU | 0,08 milligramme | Non calcolata |
| Papaïne Fonte : Carica papaya - fruit Potenza : 62.500 FCC PU | 25 milligramme | Non calcolata |
| Mentha x piperita Fonte : Extrait de Feuille Rapporto di estrazione : 10:1 Equivalente di pianta secca : 400 milligramme | 40 milligramme | Non calcolata |
| Foeniculum vulgare subsp. vulgare var. dulce Fonte : Seed extract Rapporto di estrazione : 4:1 Equivalente di pianta secca : 400 milligramme | 100 milligramme | Non calcolata |
| Lactobacillus plantarum Fonte : Cellule entière | 880.000.000 ufc | Non calcolata |
| Lactobacillus plantarum Fonte : Lp-115 | 880.000.000 ufc | Non calcolata |
| Lactobacillus acidophilus Fonte : Cellule entière | 13.740.000.000 ufc | Non calcolata |
| Lactobacillus acidophilus Fonte : LA-14 | 13.740.000.000 ufc | Non calcolata |
| Huile de poisson Fonte : Huile du corps d'Anchois Potenza : 18 % DHA (docosahexaenoic acid) | 833,33 milligramme | Non calcolata |
| Huile de poisson Fonte : Huile du corps d'Anchois Potenza : 48 % EPA (eicosapentaenoic acid) | Non precisata | Non calcolata |
| Curcuma longa Fonte : Rhizome Extract Rapporto di estrazione : 4:1 Equivalente di pianta secca : 400 milligramme | 100 milligramme | Non calcolata |
| Linum usitatissimum L. (Linaceae) Fonte : Graine(s) | 100 milligramme | Non calcolata |
| Bifidobacterium longum subsp. longum Fonte : Cellule entière | 220.000.000 ufc | Non calcolata |
| Bifidobacterium longum subsp. longum Fonte : BI-05 | 220.000.000 ufc | Non calcolata |
| Lactobacillus casei Fonte : LC-11 | 440.000.000 ufc | Non calcolata |
| Lactobacillus casei Fonte : Cellule entière | 440.000.000 ufc | Non calcolata |
| Lactobacillus rhamnosus Fonte : Cellule entière | 440.000.000 ufc | Non calcolata |
| Lactobacillus rhamnosus Fonte : LR-32 | 440.000.000 ufc | Non calcolata |
| Bromélaïne de tige Fonte : Ananas comosus var. comosus - Tige Potenza : 600.000 FCC PU | 25 milligramme | Non calcolata |
| Inuline Fonte : Cichorium intybus - racine | 2.500 milligramme | Non calcolata |
| L-Glutamine Fonte : L-Glutamine | 2.500 milligramme | Non calcolata |
| Althaea officinalis Fonte : Racine | 250 milligramme | Non calcolata |
| Plantago afra Fonte : Graine(s) | 1.250 milligramme | Non calcolata |
| Acacia Fonte : Gomme | 500 milligramme | Non calcolata |
| Protéase Fonte : Aspergillus niger - En entier Potenza : 34 FCC SAPU | 6,42 milligramme | Non calcolata |
| 4-alpha-D-Glucane glucanohydrolase Fonte : Aspergillus flavus var. oryzae - Cellule entière Potenza : 3.700 FCC DU | 16,54 milligramme | Non calcolata |
| 1,4-alpha-D-Glucane glucohydrolase Fonte : Aspergillus niger Potenza : 22 FCC AGU | 16,32 milligramme | Non calcolata |
Ingredienti non medicinali
Huile de tournesol, Hypromellose, Acide citrique, Feuille de stevia rebaudiana, Maltodextrine, Saveur, Dextrine, farine de riz, gomme acacia, Eau purifiée, Dioxyde de silicium, Son de riz, cellulose, Lécithine, Glycérine, bêta-carotène, Cire d'abeille, Gomme de xanthane, Caramel, Gélatine, Carbonate de calcium
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes | Non précisée | 1 Capsule, libération retardée | 1 Tous les jours |
| Adultes | Non précisée | 3 Gélule | Non précisée |
| Adultes | Non précisée | 2 Mesures | Non précisée |
| Adultes | Non précisée | 1 Capsule | 3 Tous les jours |
Usi autorizzati in Canada
Inflammation Support: Source of omega-3 fatty acids for the maintenance of good health. Source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Used in Herbal Medicine to aid digestion. Used in Herbal Medicine to help relieve flatulent dyspepsia (carminative). Used in Herbal Medicine as a hepatoprotectant / liver protectant. Used in Herbal Medicine to increae bile excretion by the liver (choleretic) and stimulate contraction of the gallbladder (cholagogue). Used in Herbal Medicine as an anti-inflammatory to help relieve joint pain. Healing Fibre: (Used in Herbal Medicine as a) bulk-forming laxative. (Used in Herbal Medicine to) promote(s) bowel movements by increasing bulk volume and water content. (Used in Herbal Medicine to) provide(s) gentle relief of constipation and / or irregularity. Helps restore plasma glutamine levels depleted after periods of physical stress (e.g. prolonged exhaustive exercise). Helps support immune system health after periods of physical stress. Helps support digestive system health after periods of physical stress. Helps to assist in muscle cell repair after exercise. Source of fibre for the maintenance of good health. Helps support and maintain a health digestive system. Helps stimulate the growth of healthy bacteria (such as bifidobacteria) in the intestine / gut. Prebiotic. Helps provide gentle relief of constipation and / or irregularity. Acute Care Probiotic: Source of probiotics. Helps support intestinal / gastrointestinal health. Could promote a favourable gut flora. Intensive Enzymes: Digestive enzyme. Digestive aid. Helps digest proteins. Sweet Fennel is traditionally used in Herbal Medicine to help relieve digestive disturbances including bloating and flatulence. Sweet Fennel is traditionally used in Herbal Medicine to help relieve the pain associated with menstruation. Sweet Fennel is traditionally used in Herbal Medicine as an expectorant to help relieve coughs associated with colds. Peppermint is traditionally used in Herbal Medicine to aid digestion (stomachic). Peppermint is traditionally used in Herbal Medicine to help relieve flatulent dyspepsia ( Carminative).
Testo originale in inglese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Cautions and Warnings : Inflammation Support: Consult a health care practitioner prior to use if you are pregnant or have gallstones, a bile duct obstruction, stomach ulcers or excess stomach acid. Consult a health care practitioner if symptoms persist or worsen. Store in an airtight containter, protected from light. Healing Fibre: Take 2 hours before or after taking other medications or natural health products since the absorption of these products may be delayed. Effects observed 12-24 hours after first does, and may take 2-3 days. Consult a health care practitioner if symptoms persist, worsen or if laxative effect does not occur within seven days. Consult a health care practitioner immediately if you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product. Consult a health care practitioner prior to use if you are pregnant or breastfeeding or following a low protein diet or taking medications which inhibit peristaltic movement (e.g. opioids, loperamide) or have diabetes or have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis). Do not use if experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product or have diabetes mellitus in which blood sugar is difficult to regulate or have difficulty swallowing. Hypersensitivity, such as allergy, has been known to occur due to flaxseed and inulin and also following inhaled and/or ingested psyllium; in which case, discontinue use. May cause mild gastro-intestinal discomfort (such as gas, bloating, cramps). Store in well-closed containers at room temperature. Acute Care Probiotic: If you have fever, vomiting, bloody diarrhoea or severe abdominal pain, consult a health care practitioner prior to use. If symptoms of digestive upset (e.g. diarrhea) occur, worsen, or persist beyond 3 days, discontinue use and consult a health care practitioner. If you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment), do not use this product. Intensive Enzymes: Consult a health care practitioner for use beyond 2 weeks. Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding, have anemia, gallstones, a gastrointestinal lesion/ulcer, diabetes or allergy to latex or fruits (such as avocado, banana, chestnut, passion fruit, fig, melon, mango, kiwi, pineapple, peach and tomato), are taking an anticoagulant/blood thinner, anti-nflammatory or antibiotic, or are having surgery. Do not use if you are allergic to anethole or plants of the Apiaceae / Carrot family. Hypersensitivity/allergy has been known to occur ; in which case, discontinue use. Nausea, vomiting and diarrhoea have been known to occur, in which case discontinue use (and consult a health care practitioner).
Testo originale in inglese.
Scheda del prodotto
- Altri nomi
- LGS Gut Therapy Step 1: Complete and Gentle Acute Care
- Titolare
- Lifeagen Biosciences of Florida, Inc. dba Nu-Life North America
- NPN o DIN-HM
- 80077529
- Stato
- Licenza attiva
- Data della licenza
- 17 maggio 2017
- Data di revisione
- Non indicata
- Forma
- Gélule
- Via di somministrazione
- Orale
- Tipo di domanda
- Non traditionnelle
Fonte
Scheda ufficiale Health Canada, licenza 80077529
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- Mentha x piperita
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
PEPPERMINT - MENTHA X PIPERITA
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).
Fonti citate da Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Condizione di applicazione: Essential oil.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).
Fonti citate da Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Reazioni avverse note
Condizione di applicazione: Essential oil.
When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).
Fonti citate da Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).
Fonti citate da Health Canada (2)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Foeniculum vulgare subsp. vulgare var. dulce
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
BITTER FENNEL- FOENICULUM VULGARE
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
Fonti citate da Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Condizione di applicazione: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
Fonti citate da Health Canada (1)
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Reazioni avverse note
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
Fonti citate da Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Monografia di Health Canada del 29 novembre 2024
SWEET FENNEL -FOENICULUM VULGARE
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Fonti citate da Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
Reazioni avverse note
Stop use if hypersensitivity/allergy occurs (EMA 2024).
Fonti citate da Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
- Huile de poisson
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
FISH OIL
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: Pain of rheumatoid arthritis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Condizione di applicazione: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.
- Curcuma longa
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
TURMERIC - CURCUMA LONGA - Oral
Via di somministrazione: Oral (ESCOP 2003; Blumenthal et al. 2000)
Precauzioni e avvertenze
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Fonti citate da Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Fonti citate da Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Fonti citate da Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Fonti citate da Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condizione di applicazione: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografia di Health Canada del 26 settembre 2025
Turmeric -CURCUMA LONGA - Topical
Precauzioni e avvertenze
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Controindicazioni
Do not use on deep or puncture wounds, animal bites or serious burns.
- Linum usitatissimum L. (Linaceae)
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
FLAXSEED - LINUM USITATISSIMUM
Via di somministrazione: Oral
Precauzioni e avvertenze
Si applica ai prodotti: providing 5 g or more of flaxseed per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).
Fonti citate da Health Canada (1)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).
Fonti citate da Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condizione di applicazione: Laxative; Promotion of bowel movement; Constipation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).
Fonti citate da Health Canada (2)
- Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
- Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.
Controindicazioni
Si applica ai prodotti: providing 5 g or more of flaxseed per day.
Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).
Fonti citate da Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).
Fonti citate da Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.
Reazioni avverse note
Condizione di applicazione: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).
Fonti citate da Health Canada (2)
- EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.
- L-Glutamine
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
L-Glutamine
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Althaea officinalis
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
Marshmallow - ALTHAEA OFFICINALIS - Root
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Monografia di Health Canada del 19 dicembre 2025
MARSHMALLOW - ALTHAEA OFFICINALIS - LEAF
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
La data della prova di questo elenco di ingredienti è sconosciuta.
Il prodotto è cambiato? Fotografi la confezione.
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.